insights_auto
Why is BT3 down 5,17%?
Dive Deeperchevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
0,79 €
arrow_downward
-5,17%(-0,043) 1D
14 հոկ, 08:01:17 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BT3...
Open
0,79 €
High
0,79 €
Low
0,79 €
Mkt. cap
224,87 մլն
Avg. vol.
37,00
Volume
0,00
52-wk high
1,69 €
52-wk low
0,78 €
No. of employees
75
Open
0,79 €
High
0,79 €
Low
0,79 €
Mkt. cap
224,87 մլն
Avg. vol.
37,00
Volume
0,00
52-wk high
1,69 €
52-wk low
0,78 €
No. of employees
75
News stories
From web sources and news partners
Simply Wall Street
·
18 րոպե առաջ
Palo Alto Networks (PANW) Becomes Founding Partner In Critical Infrastructure Defense Program
Investing News Network
·
35 րոպե առաջ
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
Reuters
·
2 ժամ առաջ
Wall St opens lower after hot CPI data fuels rate-hike bets
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc